Sera Prognostics is developing diagnostic tests that use proprietary biomarkers that are predictive of preterm birth, preeclampsia and other pregnancy complications. Sera aims to improve the health and development of children through early assessment of pregnancy complications that can guide medical interventions and lead to healthier deliveries. NASDAQ: SERA